Arvinas and Pfizer announce initial Phase 1b Data from the TACTIVE-U sub-study of Vepdegestrant in…
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5 per cent;…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.